Breast cancer charities have welcomed a new drug which can extend the life of some women who have an advanced form of the disease.
Perjeta has been granted a European licence after a huge global trial, part of which involved patients from the Christie Hospital in Manchester.
The drug can be used for patients with the aggressive HER-2 positive form of the disease, which accounts for a quarter of all breast cancers.
Developed by Roche, it is to be used alongside the drug Herceptin and chemotherapy and tests have found patients live an average of six months longer without their cancer getting worse, compared with those just on Herceptin and chemotherapy.
Trials are taking place to see if it can bring benefits to women with early breast cancer.
Dr Greig urged the manufacturer, the Government, NICE and the Scottish Medicines Council, to make sure it is widely available.
She added: "Through positive results like these and through work we're doing at our own dedicated research centre we're leaping closer to better outcomes for women affected by breast cancer."
NICE was in consultation about the drug and will make announce its findings in November.